BioCryst Pharma (BCRX) Misses Q4 EPS by 3c ; Offers Guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.99 +0.45%
Revenue Growth %: +13.7%
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +13.7%
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
(Updated - February 26, 2024 7:57 AM EST)
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.28), $0.03 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $93.4 million versus the consensus estimate of $89.97 million.
GUIDANCE:
BioCryst Pharma sees FY2024 ORLADEYO revenue of $380-400 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
- Pfizer reafffirms 2026 guidance after CFO transition announcement
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
